of T-dose). Stepwise multivariate Cox regression models revealed fundamental differences in inter-individual effects: hazard ratios for loss of BMI/WC were significantly higher in those subjects with younger age, lower baseline T and higher ratios of delta testosterone over delta estradiol levels induced by treatment (all p<0.01). Advanced age, higher baseline BMI and higher delta estradiol levels resulted in significantly higher hazard ratios for prostate growth/increase in PSA or hematocrit (all p<0.01). Overall, effects were attenuated, but still significant, in subjects with androgen receptor gene CAG repeat length >24, in those with KS or men with non-classical hypogonadism (using non-KS primary hypogonadism as referent, all p<0.05).
INTRODUCTION AND OBJECTIVES: Studies have demonstrated that metabolic syndrome (MetS) is associated with low testosterone (T) levels. However the incremental effect of every MetS component in predicting testosterone deficiency (TD) has not been well explored in the literature. The primary goal of this study was to investigate the association of MetS and low T levels in men from 40 to 80 years of age, while investigating the cumulative effect of the syndrome components METHODS: We reviewed records of all men who presented to our men's health clinic from January 2014 to August 2016. We evaluated age, presence of hypertension, waist circumference (WC), blood glucose level and the serum lipid profile (HDL and triglycerides -TGL), and MetS was considered present when 3 or more factors were present. TD was defined as serum total T <300 ng/dL. Univariable analyses were performed to assess the association variables and T levels. ROC curves analyses were performed to evaluate diagnostic accuracy of each MetS component in predicting TD.
RESULTS: The study comprised 902 men with a mean age of 57.2 AE 9.85 years. The overall prevalence of low T levels was 23.4% and it was similar across all age subgroups: age 40-49 years (y) 22.7%, 50-59y 23.1%, 60-69y 23.8%, and 70-79y 24.4%, p¼0.25. The diagnosis of MetS was established in 27.9% of subjects and was associated with TD (OR¼3. Table 1. CONCLUSIONS: There is an increased prevalence of TD with increasing number of MetS components. WC was the best predictor of TD in our population and age was not associated with lower T levels INTRODUCTION AND OBJECTIVES: PSA secretion is a testosterone (T) dependent process. There is published data suggesting that low serum total T level is an independent predictor of higher stage, higher grade prostate cancer. However, the link between men diagnosed with prostate cancer with low PSA values and T deficiency (TD) has not been explored before.
METHODS: All men diagnosed with prostate cancer since 2000 that had a record of pre-treatment early morning total T level measurement were included in the analysis. We analyzed demographic, clinical and pathological data. Patients were stratified according to pretreatment PSA levels: 0-2; 2.1-4; >4 ng/ml. TD was defined as total T < 300 ng/dL. We evaluated the relationship between these PSA groups and TD. Age, diabetes, and hyperlipidemia were also included in both univariate and multivariable analyses.
RESULTS: Mean age of 349 men was 64AE8 years. The distribution by PSA group was: 5% 0-2, 16% 2.1-4, and 79% >4. The mean T level across the entire cohort was 358AE192 ng/dl. Overall, 38% had a T level < 300 ng/dl; 63% > 300 ng/dl. 9% had diabetes, 10% had hyperlipidemia. The mean T leve by PSA group was: 265AE168 0-2; 328AE210 2.1-4; and 371AE189 >4, p¼0.03. The percentage of men with TD by PSA group was: 53% 0-2; 49% 2.1-4; and 35% >4, p¼0.05. The percentage of men with extremely low T levels (<200) by PSA group was: 35% 0-2; 22% 2.1-4; and 13% >4, p¼0.01. Age, diabetes, and hyperlipidemia were not related to T level grouping on univariate analyses (p¼0.35 to p¼0.81). On multivariable analysis, PSA 0-2 compared to PSA >4: OR¼2.1, 95% CI: 0.82-5.36, p¼0.12; PSA 2.1-4 compared to PSA >4: OR¼1.9, 95% CI: 1.02-3.34, p¼0.04. PSA 0-2 compared to PSA >4 was not significant due to low sample size.
CONCLUSIONS: Low PSA levels predict TD in a cohort of patients with prostate cancer. This finding suggests a possible benefit of adding total T level measurement when a patient with low PSA is diagnosed with prostate cancer.
Source of Funding: None

MP91-10 TESTOSTERONE RECOVERY PROFILES AFTER CESSATION OF ANDROGEN DEPRIVATION THERAPY (ADT)
INTRODUCTION AND OBJECTIVES: It has been demonstrated that the combination use of ADT improves overall and cancerspecific survival in men with unfavorable prostate cancer (PCa). After cessation of ADT, testosterone (T) levels are expected to recover from castrate to normal levels. However, very little is known about T recovery profiles in this population, and many patients remain on castrate levels indefinitely. The aim of this study was to evaluate T recovery after cessation of ADT in PCa patients.
METHODS: We reviewed our prospectively maintained database for PCa patients who received ADT therapy at our institution. Vol. 197, No. 4S, Supplement, Tuesday, May 16, 2017 THE JOURNAL OF UROLOGY â e1221
Serum early morning total T (TT) levels were measured at baseline and periodically after ADT cessation. Multivariable time-to-event analysis (Cox proportional hazards) was performed to determine predictors of TT recovery after ADT cessation and included the following variables: patient age, baseline T level, and duration of ADT. RESULTS: 1641 men with a mean age of 66 (43-94) years were included. Primary treatment for PCa was RP in 36%, while the remainder had either RT or primary ADT. The majority received a GnRH agonist as mainstay for ADT. Mean duration of ADT was 28.8 AE 39 months [0.5 to 324]. Distribution of ADT exposure was: <6 months (m) 33%, 6-12m 19%, 12-24m 16%, >24m 33%. Median follow-up was 47.5 AE 45 months. Mean TT values were: baseline 358 ng/dl, 6-12m post ADT cessation 96 ng/dl, 12-18 174 ng/dl, 18-24m 228 ng/dl, >24m 273 ng/dl. At last follow-up: 77% men had TT level above castrate level, 45% had TT >300ng/dl and 39% returned to pre-treatment TT level. Age over 65 years, ADT duration of 6 months or greater, and baseline T of less than 400 ng/dl were all significantly associated with a slower recovery time. Multivariable analysis data are presented in the Table. CONCLUSIONS: Approximately one third of patients undergoing ADT for prostate cancer at our center had return of TT level back to pre-treatment level with 23% maintaining castrate TT levels at 24 months after ADT cessation.
Source of Funding: None
MP91-11 POSITIVE EFFECTS OF LONG-TERM TREATMENT WITH TESTOSTERONE UNDECANOATE INJECTIONS (TU) ON RENAL FUNCTION IN HYPOGONADAL MEN: REAL-LIFE DATA FROM A PROSPECTIVE CONTROLLED REGISTRY STUDY
Aksam Yassin*, Dany-Jan Yassin, Norderstedt-Hamburg, Germany; Gheorge Doros, Abdulmaged Traish, Boston, MA INTRODUCTION AND OBJECTIVES: A registry was established to assess long-term effectiveness and safety of testosterone undecanoate injections (TU) in a urological setting in comparison to an untreated hypogonadal control group. Parameters related to renal function were measured to gain insight on effects of testosterone therapy (TTh) on renal function. METHODS: Observational, prospective, cumulative registry study in 505 men (age: 61.4 AE 9.7 years) with total testosterone (T) levels 350 ng/dL and symptoms of hypogonadism. 321 men received parenteral TU 1000 mg/12 weeks following an initial 6-week interval for up to 12 years (T-group). 184 men had opted against TTh and served as controls (CTRL). 8-year data were analyzed. Renal profile was assessed by (Creatinine, Urea, Uric acid and Glomerular filtration rate measured according to Mayo Clinic setting) RESULTS: Creatinine decreased from 1.14AE0.18 to 1.07AE0.8 mg/dL in the T-group and increased from 0.99AE0.25 to 1.13AE0.53 in CTRL. Uric acid decreased from 6.8AE1.5 to 5.5AE1.6 mg/dL in the T-group (p<0.0001) and from 5.7AE1.5 to 5.2AE1.5 mg/dL in CTRL (p<0.01). Urea was only available for the T-group and decreased from 47.5AE12.0 to 31.7AE12.9 mg/dL (p<0.0001). Glomerular filtration rate (GFR) increased from 86.6AE12.8 to 98.5AE8.6 mL/min/1.73 m2 in the T-group and decreased from 90.8AE20.2 to 87.0AE26.0 mL/min/1.73 m2 in CTRL (p<0.0001 for both). g-GT decreased from 39.31AE11.62 to 28.95AE7.57 U/L in the T-group (p<0.0001) and increased from 37.79AE29.55 to 39.5AE26.71 U/L in CTRL (p<0.0005). Bilirubin decreased from 1.64AE4.13 to 1.21AE1.89 mg/dL in the T-group (p<0.05) and increased from 1.04AE7.08 to 1.12AE1.96 mg/dL in CTRL (NS). AST remained stable in both groups, ALT declined slightly in both groups. Medication adherence in the T-group was 100 per cent as all injections were administered in the office and documented. There were 25 deaths (7.8%) in the T-group of which 11 (44%) were cardiovascular. In CTRL, 28 patients (15.2%) died, and all deaths (100%) were attributed to cardiovascular causes.
CONCLUSIONS: Long-term TTh with TU in an unselected hypogonadal men resulted in improvement of renal function, whereas there was a slight worsening in untreated controls. Since renal function may be related to cardiovascular risk, the observed changes may have contributed to a reduction in mortality. METHODS: Registry study in 656 men with testosterone 350 ng/dL and hypogonadal symptoms. 360 received TU 1000 mg/12 weeks following an initial 6-week interval (T-group). 296 men opted against TTh and served as controls (CTRL). 8-year data are presented. Changes over time between groups were compared by a mixed effects model for repeated measures with a random effect for intercept and fixed effects for time, group and their interaction. Changes were adjusted for age, weight, waist circumference, blood pressure, fasting glucose, lipids and quality of life to account for baseline differences between groups. In order to further validate results, propensity matching was performed for baseline age, BMI, and waist circumference. 82 men in each group fulfilled criteria. RESULTS: Total group: mean age was 57.4AE7.3 years in the T-group and 64.8AE4.3 in CTRL, median follow-up time 7 years for both. In the T-group, T levels rose from 285AE37 ng/dL to trough levels (measured prior to the following injection) between 450 and 500 ng/dL (p<0.0001). In CTRL, T levels remained stable between 260 and 280 ng/dL. In the T group, IIEF-EF (maximum score: 30) increased from 19.5AE5.0 to 25.9AE3.0 with a change from baseline of 6.0 points. The improvement was statistically significant for the first four years and remained statistically significant vs baseline throughout the observation time and stable compared to previous years. In the CTRL group, IIEF-EF decreased from 20.5AE3.1 to 11.7AE1.6 after 8 years by 9.5 points (p<0.0001 for both). Propensity-matched group: mean age was 61.7AE5.1 years in the T-group and 61.6AE2.9 in CTRL, median follow-up time 8 years in the T-group and 7 in CTRL. In the T-group, T levels rose from 277AE41 ng/dL to trough levels between 470 and 515 ng/dL (p<0.0001). In CTRL, T levels remained stable between 250 and 280 ng/dL. In the T group, IIEF-EF (maximum score: 30) increased from 19.5AE5.6 to 25.8AE3.9 with a change from baseline of 5.9 points. The improvement was statistically significant for the first three years and remained statistically significant vs baseline throughout the observation time and stable compared to previous years. In CTRL, IIEF-EF decreased from 20.2AE3.3 to 12.4AE1.0 after 8 years by 8.6 points (p<0.0001 for both).
Source of
CONCLUSIONS: Erectile function is improved and preserved for a prolonged period of time by TTh in hypogonadal men and deteriorates in untreated hypogonadal men.
Source of Funding: Bayer Pharma AG partially funded data entry and statistical analyses.
